Siren Biotechnology, Inc.

Siren Biotechnology is the world's first #AAV #GeneTherapy company targeting #cancer.

[Siren Biotechnology, Inc. @SirenBio]

As #GrayMay comes to a close, we're reminded of why we show up every day at @SirenBio.

High-grade gliomas are among the hardest cancers to treat. Survival is still measured in months for most patients, and meaningful new options have been slow to arrive.

There are now two open INDs for SRN-101, our lead asset in recurrent high-grade glioma, and every step forward is motivated by the patients, families, and caregivers facing this disease head-on.

Let's sound the alarm against cancer.

#GrayMay #BrainTumorAwarenessMonth #GeneTherapy #Cancer

[Siren Biotechnology, Inc. @SirenBio]

Our team had a wonderful time connecting with collaborators and fellow #AAV #GeneTherapy experts last week at #ASGCT2026! Highlights were talking great science at our annual Siren happy hour and presenting some of our large animal and CMC data. Missed our poster and talk? Check them out on our website: https://t.co/swNFZG5W3a

[Siren Biotechnology, Inc. @SirenBio]

@SirenBio is headed to #ASGCT2026 next week! Find us at the events below to learn more about our path to the clinic with #SRN101, our lead AAV immuno #genetherapy for #cancer. See you in Boston!

Happy Hour RSVP: https://t.co/aIbxmeMqaW

[Siren Biotechnology, Inc. @SirenBio]

BIG moment for @SirenBio 🚨

We’re thrilled to share that our first peer-reviewed manuscript is now published in @CellPressNews Molecular Therapy Oncology - and we’re heading to @ASGCTherapy 2026 with even more data to share!

This publication showcases the foundation of our Universal AAV Immuno-Gene Therapy platform, including groundbreaking preclinical data in high-grade glioma, one of the toughest cancers with the greatest unmet need.

Huge thanks to our team and collaborators for supporting this work!

👉 Read the full press release here: https://t.co/lFY0oai0iv

👉 Access the open access manuscript here: https://t.co/xnAkq0V6a3

Want more, like our IND large animal data?! Come find us at #ASGCT2026!

#AAV #GeneTherapy #Immunotherapy #Oncology #Publication

[Siren Biotechnology, Inc. @SirenBio]

Join @SirenBio's CEO @Nicole_Paulk and other industry leaders at the NORD Scientific Symposium next week! We’ll be sharing ways to bring community members in as company stakeholders through community fundraising. Register here: https://t.co/387ZkmmMqJ

[Siren Biotechnology, Inc. @SirenBio]

Thrilled to see @SirenBio SAB member Beverly Davidson recognized with the Outstanding Achievement Award by @ASGCTherapy! A well-deserved honor celebrating her pioneering work and lasting impact on the field 🌟

[ASGCT @ASGCTherapy]

Congratulations to Beverly L. Davidson, Ph.D., recipient of the 2026 ASGCT Outstanding Achievement Award! As the Society’s highest honor, this award recognizes Dr. Davidson’s pioneering research into the molecular mechanisms of inherited brain diseases and her leadership in developing and testing gene-based therapeutic strategies.

Join us in celebrating her incredible contributions to the field at #ASGCT2026! Meet all of our 2026 award winners: https://t.co/9lGXxpTQyv

[Siren Biotechnology, Inc. @SirenBio]

Big news for SRN-101 🚀 The FDA has cleared a second IND to launch a Phase 1 trial with SRN-101 in recurrent high-grade glioma. This investigator-initiated study, led by Dr. Nicholas Butowski at @UCSF, marks an exciting step forward in expanding clinical evaluation of SRN-101. We’re so proud to support the UCSF team as they advance this important work for patients in need!

Learn more: https://t.co/wq0lIIFzba

[Siren Biotechnology, Inc. @SirenBio]

On the heels of IND clearance for SRN-101, we are thrilled to announce another major milestone at @SirenBio! 🚀

The FDA has granted #FastTrack Designation to SRN-101, our lead Universal #AAV Immuno-Gene Therapy candidate for recurrent high-grade glioma 🧠

Fast Track status reinforces the urgency and potential impact of bringing this first-of-its-kind therapy to patients.

Momentum is building and we’re just getting started! 💥

[Siren Biotechnology, Inc. @SirenBio]

The @SirenBio team is heading to Phacilitate #ATW26 next week. Our Founder & CEO, @Nicole_Paulk, and our SVP of Vector Development Nathalie Clement look forward to meeting with partners, peers, and fellow leaders pushing the field forward. If you’ll be in San Diego, we’d love to see you!

[Siren Biotechnology, Inc. @SirenBio]

A big day of celebration here at @SirenBio! 🎉 We’re thrilled to share that the FDA has cleared our first IND for SRN-101, enabling our Phase I/II trial of what we believe is the first #AAV #GeneTherapy for any #cancer clinically.

This milestone marks a major step forward in bringing SRN-101 to patients with recurrent high-grade glioma. Huge congratulations to our incredible team, advisors, and partners who helped make this moment possible!

[Siren Biotechnology, Inc. @SirenBio]

It’s a busy start to 2026 at @SirenBio! We’re excited to be out in full force at #JPM2026, #ATW2026, and #BiocomGPIC. Come meet with us at:
📍 JPM Jan 12-15 | San Francisco, CA
📍 Advanced Therapies Feb 9-12 | San Diego, CA
📍 Biocom Feb 24-26 | La Jolla, CA
If you’ll be there too, let’s connect!

[Siren Biotechnology, Inc. @SirenBio]

@ASGCTherapy We hope folks enjoy this! #GeneTherapy

[Siren Biotechnology, Inc. @SirenBio]

Happy holidays from the @SirenBio team!🎄Our key moments were submitting our first IND to the FDA (today!) and closing our first-ever community investment round. But these can’t overshadow all the other accomplishments our team had in 2025. In all, we counted:
⚡ 8 new cancer indications tested
💸 1,529 new investors
✍️ First IND filed
🧠 3 new SAB members
🧪 10 formal assay qualifications
🏅 3 big awards received
🧬 100+ new constructs screened
💪 1 cancer diagnosis AND recovery!
💼 7 conferences attended
🐣 1 new baby
📆 50 weekly syncs and 26 lab meetings
🥹 1 proud team with ♾️ accomplishments…make that ♾️ + 1! 💛
Stay tuned for our 2026 tally…

[Siren Biotechnology, Inc. @SirenBio]

🚀 Hey #founders and builders! Thinking about opening your own community investment round?

We just dropped the full recording of our webinar where the @SirenBio team walks through how we approached - and successfully ran - our own community round.

It’s not legal or financial advice, just an honest look at what worked for us (and what we learned along the way).

If you’re a founder curious about bringing your supporters in as investors, this is a great place to start.

Featuring:
@Nicole_Paulk and Akela Kuwahara from @SirenBio
Nina Ekmescic from Capital Department
Jonny Price from @Wefunder

🎥 Watch the full video here: https://t.co/Xmgrlx5o2t

#StartupFunding #CommunityRound #BiotechStartups #Founders

[Siren Biotechnology, Inc. @SirenBio]

@FrankJWoods2 $4.2 million 😎

[Siren Biotechnology, Inc. @SirenBio]

Final Call: @SirenBio's Community Round Is Closing Soon! 🚨

When we opened this raise, we set out to do something bold – not just in the lab, but in how we build this company. We invited you, our community, to help shape the future of #cancer care.

And the response? Absolutely incredible.

Since launching this round, we’ve hit major milestones:
💸 $3M+ raised
👥 1,250+ investors have joined the mission
🏆 Named Start-Up of the Year at Advanced Therapies Week
🎤 Took the stage at SXSW to spotlight our universal gene therapy
🎖️ First patent granted protecting core tech behind SRN-101
🐖 Large-animal studies launched to advance toward human trials
🧬 Successful Pre-IND meeting with the FDA, keeping us on track for the clinic in 2026
👩‍🔬 GMP production of SRN-101 is officially underway

Our community round is closing in *just a few weeks*. If you’ve been thinking about investing (or upping your stake), now is your chance.

Invest or increase your investment today: https://t.co/6DY1qJPR3C

Here’s to a strong close!! 🚀

[Siren Biotechnology, Inc. @SirenBio]

Curious what it was like to launch one of the first ever biotech community investment rounds? We're hosting a webinar for founders and builders next week! RSVP here: https://t.co/VAbR7BkBJK

[Siren Biotechnology, Inc. @SirenBio]

Wow — what a way to close out our first-ever community round! 🎉

We’re incredibly grateful to the 1,600+ investors who joined our mission and helped us raise over $4.2 million to support the next generation of cancer gene therapy.

This round wasn’t just about funding. It was about opening the doors to patients, families, advocates, doctors and anyone who believes cancer care has to be faster, smarter, and more effective.

We’re honored to have you with us on this journey.

📝Check out our final campaign update on Wefunder: https://t.co/KLwBHs1Uyn

Here’s to an exciting chapter ahead!

[Siren Biotechnology, Inc. @SirenBio]

Only a few hours left, and that’s it! ⏳
The momentum in these final hours has been incredible. We’re closing in on $4M raised from over 1,500 investors, and we couldn’t be more proud of what this community has built.

Here’s why investors are excited about Siren:
🧬Universal AAV gene therapy for cancer
💸$28M raised from top-tier VCs including Founders Fund and Lux Capital
🏆Named 2025 Start-Up of the Year at Phacilitate Advanced Therapies Week
🔬550+ animals treated with curative preclinical data
🧪Clinical trials targeted for 2026
🎓Team from Stanford, UCSF, Duke, Mount Sinai, and Roche
🎖️First patent family awarded
👑Called “perhaps the most de-risked pharma startup” by Kingscrowd
🌍Tackling a $3.2B+ global market for brain tumor therapeutics
🎙️Featured at SXSW 2025

We opened this round to give more people a seat at the table in building the future of cancer care and we’ve been blown away by your belief, support, and boldness. ❤️

🚨Join us or increase your stake before our round closes for good → https://t.co/nvIEnw0LbA

[Siren Biotechnology, Inc. @SirenBio]

@woodien @harmonybabyfood Woot woot 🎉

https://t.co/wZrAqvp6UQ

[Siren Biotechnology, Inc. @SirenBio]

🚨We’re almost at the finish line – Siren’s community investment round closes TONIGHT

This is your final chance to invest in the company developing a universal AAV immuno-gene therapy for cancer.

💸 $28M raised from top VCs including Founders Fund, Lux Capital & more
🧬 $3.8M+ raised from 1,500+ community investors (and counting!)
🏆 2025 Start-Up of the Year at Phacilitate Advanced Therapies Week
🧠 Game-changing universal AAV gene therapy
🔬 550+ animals treated with curative preclinical data
🧪 Targeting clinical trials in 2026, a critical step toward FDA approval
🎓 Powerhouse team from Stanford, UCSF, Duke, Mount Sinai, and Roche
🌍 $3.2B global market for brain tumor therapeutics

Let’s bring a radically new kind of cancer treatment into the world.

🎯Invest or increase your investment before 11:59pm EST:
👉https://t.co/nvIEnw1j18

Here we go!